Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.05
30.34
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Pacific Shuanglin Bio pharmacy Co Ltd
Net Income (Common)
Pacific Shuanglin Bio pharmacy Co Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pacific Shuanglin Bio pharmacy Co Ltd
SZSE:000403
|
Net Income (Common)
¥828.6m
|
CAGR 3-Years
29%
|
CAGR 5-Years
46%
|
CAGR 10-Years
23%
|
|
|
Beigene Ltd
HKEX:6160
|
Net Income (Common)
-¥6.7B
|
CAGR 3-Years
16%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Net Income (Common)
-¥1.3B
|
CAGR 3-Years
3%
|
CAGR 5-Years
28%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Net Income (Common)
¥1.2B
|
CAGR 3-Years
23%
|
CAGR 5-Years
34%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Net Income (Common)
¥3.7B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
12%
|
CAGR 10-Years
39%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Net Income (Common)
¥1.9B
|
CAGR 3-Years
62%
|
CAGR 5-Years
72%
|
CAGR 10-Years
N/A
|
|
Pacific Shuanglin Bio pharmacy Co Ltd
Glance View
In the intricate web of China's burgeoning pharmaceutical landscape, Pacific Shuanglin Bio-Pharmacy Co., Ltd. stands out as a dynamic entity making waves in the biopharmaceutical sector. Founded with a vision to innovate and provide advanced healthcare solutions, the company has anchored its operations in the research, development, manufacturing, and marketing of a diverse range of bio-products and pharmaceutical drugs. The core of their business revolves around biotechnology, leveraging cutting-edge techniques to develop treatments aimed at addressing critical and complex health issues. Their product portfolio is robust, comprising antibiotics, cardiovascular medications, and other critical therapeutic areas, which emphasizes their capacity to adapt and thrive in a competitive market. Central to Pacific Shuanglin's success is its steadfast commitment to research and innovation. By investing heavily in R&D, the company not only ensures a steady pipeline of new products but also enhances the efficacy and safety of existing ones. This strategic focus not only stimulates growth but also fortifies their competitive edge. Their revenue model predominantly hinges on the successful commercialization of these pharmaceutical innovations, reinforcing a cycle of continual improvement and reinvestment in new medical solutions. Through strategic partnerships and a well-established distribution network, Pacific Shuanglin effectively reaches its target markets, both domestically and internationally, ensuring that their advanced medical products make a tangible difference in the lives of patients.
See Also
What is Pacific Shuanglin Bio pharmacy Co Ltd's Net Income (Common)?
Net Income (Common)
828.6m
CNY
Based on the financial report for Sep 30, 2024, Pacific Shuanglin Bio pharmacy Co Ltd's Net Income (Common) amounts to 828.6m CNY.
What is Pacific Shuanglin Bio pharmacy Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
23%
Over the last year, the Net Income (Common) growth was 74%. The average annual Net Income (Common) growth rates for Pacific Shuanglin Bio pharmacy Co Ltd have been 29% over the past three years , 46% over the past five years , and 23% over the past ten years .
You don't have any saved screeners yet
